PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival - Results of Phase III Trial for Bevacizumab (Avastin®) Published in the New England Journal of Medicine - MDxHealth.com
MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2014/03/04 - Results of Phase III Trial for Bevacizumab (Avastin®) Published in the New England Journal of Medicine - MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the publication in the New England Journal of Medicine of a phase III randomized trial of bevacizumab, brand name Avastin®, for newly diagnosed glioblastoma patients, confirms the clinical utility of its PredictMDx® for Glioblastoma test.

MDxHealth's PredictMDx for Glioblastoma (MGMT) test, included in the 2013 National Comprehensive Cancer Network (NCCN) Senior Adult Oncology Guidelines, provides actionable information to oncologists seeking to provide personalized treatment of elderly patients with glioblastoma (GBM), the most common and most aggressive malignant primary brain tumor in humans. The test assesses the methylation status of the MGMT gene, which is a key DNA repair component. If the MGMT gene is methylated, cancer patients have shown improved response to alkylating drug therapy. Studies on thousands of clinical trial patients have demonstrated that PredictMDx for Glioblastoma can help oncologists identify newly diagnosed glioblastoma patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents).

Dr Gilbert et al describe the results of the phase III study,"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma" (N Engl J Med 2014; 370:699-708, February 20, 2014) in which patients were prospectively randomized into the treatment arms based on MDxHealth's MGMT (O6-methylguanine-DNA methyl transferase) methylation test results. MGMT methylation status was shown to be prognostic for progression-free survival (PFS) and overall survival (OS), regardless of therapies investigated in this study. The median PFS for patients with unmethylated tumors was 8.2 months vs. 14.1 months in the patients with MGMT methylated tumors, with a hazard ratio of 1.67 (95% CI of 1.36 to 2.05, p<0.001). The median OS for patients with MGMT unmethylated tumors was 14.3 months compared with 23.2 months in patients with MGMT methylated tumors. The hazard ratio for death in patients with unmethylated tumors was reported as 2.10 (95% CI of 1.65 to 2.68, p<0.001).

"As shown in previous published studies these results again confirm the prognostic value of our PredictMDx test in glioblastoma. These results demonstrate the clinical importance of using molecular biomarkers, like MGMT, to improve patient stratification and the current standard of care," stated Prof. Dr. Wim van Criekinge, Chief Scientific Officer of MDxHealth.

About MDxHealth®
MDxHealth (formerly OncoMethylome Sciences) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx® for Prostate Cancer, has been validated to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer, thereby aiding in the reduction of unnecessary repeat biopsies. MDxHealth (mdxhealth.com) helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers.

Contacts
Mike Sinclair (media) - Halsin Partners
UK: +44(0)20 7318 2955 / C: +44(0)79 6802 2075
E: msinclair[.]halsin.com.

Len Hall (investors) - Allen & Caron, Inc
US: +1 949 474 4300 - E: len[.]allencaron.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


MDxHealth's PredictMDx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

MDxHealth, Inc. |
Publisher Contact: Dr. Jan Groen - MDxHealth.com 
949-812-6979 / +32 4 364 20 70 info[.]mdxhealth.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MDxHealth, Inc. / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)